Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Sagimet Biosciences Reported Denifanstat Met All Primary And Secondary Endpoints In A Phase 3 Clinical Trial For The Treatment Of Moderate To Severe Acne Vulgaris Conducted By Sagimet's License Partner Ascletis Bioscience Co. Ltd. (Ascletis) In China

Author: Benzinga Newsdesk | June 04, 2025 04:03am

Posted In: SGMT